NCT05925647

The Effects of Mesenchymal Stem Cell Secretome in Rheumatoid Arthritis Patients

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Universitas Sebelas Maret · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This research is a clinical trial of administering mesenchymal stem cell secretome to rheumatoid arthritis patients.

Detailed description

This research is experimental. The research subjects were 30 rheumatoid arthritis patients. The control group received a placebo, and the treatment group received mesenchymal stem cell secretome on the 1st, 2nd, 3rd, 4th, 5th, 6th, 7th, 14th, 21st, and 28th. The data collected were erythroblastic acidity, hsCRP, interlukin 6, DAS-28, and assessment of drug side effects before and after therapy. Statistical test with paired difference test with p\<0.05

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	Messenchymal stem cell secretome	Mesenchymal stem cell secretome obtained from Kalbe Pharma Company
DRUG	Placebo	NaCl 0,9% infusion

Timeline

• Start date: 2022-08-01
• Primary completion: 2023-02-28
• Completion: 2023-03-09
• First posted: 2023-06-29
• Last updated: 2023-06-29

Locations

1 site across 1 country: Indonesia